PT99062A - Processo para a preparacao de derivados de xantina - Google Patents

Processo para a preparacao de derivados de xantina Download PDF

Info

Publication number
PT99062A
PT99062A PT99062A PT9906291A PT99062A PT 99062 A PT99062 A PT 99062A PT 99062 A PT99062 A PT 99062A PT 9906291 A PT9906291 A PT 9906291A PT 99062 A PT99062 A PT 99062A
Authority
PT
Portugal
Prior art keywords
cyclopropylmethyl
group
compound
xanthine
formula
Prior art date
Application number
PT99062A
Other languages
English (en)
Portuguese (pt)
Inventor
Derek Richard Buckle
David Glynn Smith
Ashley Edward Fenwick
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Publication of PT99062A publication Critical patent/PT99062A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
PT99062A 1990-09-26 1991-09-25 Processo para a preparacao de derivados de xantina PT99062A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020959A GB9020959D0 (en) 1990-09-26 1990-09-26 Novel compounds

Publications (1)

Publication Number Publication Date
PT99062A true PT99062A (pt) 1992-08-31

Family

ID=10682788

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99062A PT99062A (pt) 1990-09-26 1991-09-25 Processo para a preparacao de derivados de xantina

Country Status (12)

Country Link
EP (1) EP0550570A1 (fr)
JP (1) JPH06501251A (fr)
KR (1) KR930702351A (fr)
AU (1) AU653364B2 (fr)
CA (1) CA2092430A1 (fr)
GB (1) GB9020959D0 (fr)
IE (1) IE913350A1 (fr)
MX (1) MX9101237A (fr)
NZ (1) NZ239921A (fr)
PT (1) PT99062A (fr)
WO (1) WO1992005175A1 (fr)
ZA (1) ZA917610B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69132291T2 (de) * 1990-12-21 2000-12-14 Beecham Group Plc Xanthinderivate
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
US5817662A (en) * 1992-11-09 1998-10-06 Cell Therapeutics, Inc. Substituted amino alkyl compounds
US5646156A (en) * 1994-04-25 1997-07-08 Merck & Co., Inc. Inhibition of eosinophil activation through A3 adenosine receptor antagonism
EP0814809B1 (fr) * 1994-12-13 2003-08-13 Euroceltique S.A. Aryle thioxanthines
WO1996036638A1 (fr) * 1995-05-19 1996-11-21 Chiroscience Limited Xanthines et leur utilisation therapeutique
MA24682A1 (fr) * 1997-10-23 1999-07-01 Smithkline Beecham Corp Formes polymorphes nouvelles de cipamfylline, procede pour leur preparation et compositions les contenant
IL153182A0 (en) * 2000-07-04 2003-06-24 Novo Nordisk As Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
HUP0301622A3 (en) 2000-07-04 2006-05-29 Novo Nordisk As Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
EP1421084B1 (fr) 2001-08-28 2008-05-14 Schering Corporation Inhibiteurs polycycliques de la phosphodiesterase v de la guanine
EP1442042A1 (fr) 2001-11-09 2004-08-04 Schering Corporation Inhibiteurs de la phosphodiesterase v de derives polycycliques de guanine
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
WO2004009091A1 (fr) 2002-06-17 2004-01-29 Glaxo Group Limited Agonistes des recepteurs x du foie
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2533715A1 (fr) 2003-07-31 2005-02-10 Schering Corporation Metabolite de l'inhibiteur de xanthine phosphodiesterase 5 et derives de ce metabolite, utiles dans le traitement de la dyserection
EP1697363A2 (fr) * 2003-12-16 2006-09-06 Ranbaxy Laboratories Limited Composés purine pouvant être utilisés en tant qu'inhibiteurs de phosphodiestérase de type iv
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004030502A1 (de) 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004037554A1 (de) 2004-08-03 2006-03-16 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkylthio-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004039507A1 (de) 2004-08-14 2006-03-02 Sanofi-Aventis Deutschland Gmbh Substituierte 8-Aminoalkoxi-xanthine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (fr) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG Compositions d'inhibiteurs de la DPP IV
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EP2344195A2 (fr) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Polythérapie pour le traitement du diabète et des états pathologiques apparentés
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (fr) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin pour son utilisation dans le traitement de l'albuminurie et des maladies liees au rein
WO2013174767A1 (fr) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh Dérivé de xanthine en tant qu'inhibiteur de la dpp-4 à utiliser dans la modification de l'apport alimentaire et dans la régulation des préférences alimentaires
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392968B (de) * 1987-01-30 1991-07-25 Sandoz Ag Neue xanthinderivate
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
GB9020921D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
WO1992007852A1 (fr) * 1990-10-25 1992-05-14 G.D. Searle & Co. Composes de xanthine de biphenylalkyle pour le traitement de troubles cardiovasculaires

Also Published As

Publication number Publication date
KR930702351A (ko) 1993-09-08
GB9020959D0 (en) 1990-11-07
ZA917610B (en) 1992-09-30
WO1992005175A1 (fr) 1992-04-02
MX9101237A (es) 1992-05-04
AU653364B2 (en) 1994-09-29
JPH06501251A (ja) 1994-02-10
NZ239921A (en) 1993-12-23
EP0550570A1 (fr) 1993-07-14
AU8541391A (en) 1992-04-15
IE913350A1 (en) 1992-04-08
CA2092430A1 (fr) 1992-03-27

Similar Documents

Publication Publication Date Title
PT99062A (pt) Processo para a preparacao de derivados de xantina
US5981535A (en) Substituted xanthines and their use in the treatment of cerebrovascular disorders and other diseases
US5409934A (en) Xanthine derivatives
EP0310950B1 (fr) Quinoléines intermédiaires pour la synthèse des 1H-imidazo[4,5-c]quinoléines et 1H-imidazo[4,5-c]quinoléine-4-amines
NZ232602A (en) Imidazo quinoline derivatives, preparation and pharmaceutical compositions thereof
EP1165558B1 (fr) Derives de pyrimido 6,1-a] isoquinolein-4-one et leur utilisation en medecine
CS203093B2 (en) Method of preparing substituted purines
SK99795A3 (en) Imidazopyrimidines, method of their preparation, treating with their contents and use
EP0641344A1 (fr) Xanthines 8-substituees utilisees en tant qu'inhibiteurs de la phosphodiesterase
US7550475B2 (en) Condensed polycyclic compounds
AU650679B2 (en) Xanthines
EP0242230A2 (fr) Dérivés de pyrido[1,2-a]pyrimidine
EP0097468A2 (fr) Thio-naphtotriazoles, leurs procédés de préparation, et leur application dans le traitement d'allergies
NZ241942A (en) Quinoline derivatives

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19920408

FC3A Refusal

Effective date: 19981117